About QED Therapeutics
Who we are
A subsidiary of BridgeBio, QED focuses on precision medicine for FGFR-driven cancers and diseases. We live by our name: QED, derived from the Latin “Quod Erat Demonstrandum” — Thus, It Has Been Proven.
Our business is inspired by our values.
- Put patients first
- Act nimbly
- Think independently
- Be radically transparent
What we do
With singular focus, QED is devoted to the development of our investigational candidate, infigratinib. A first-in-class, selective, tyrosine kinase inhibitor, infigratinib has promising early clinical data in patients with previously treated, FGFR-driven cholangiocarcinoma and metastatic urothelial carcinoma, as well as preclinical studies in achondroplasia. Future studies will investigate infigratinib for additional FGFR-driven tumor types and rare disorders.
FGFR=fibroblast growth factor receptor.